Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor

ÜNEK, İLKAY; ÇELTİK, AYGÜL; Yener, S.; YAVUZŞEN, TUĞBA; Alacacioglu, A.; Cokmert, S.; Oztop, I.; Demirkan, HATİCE; Dicle, O.; Sagol, ÖZGÜL; BEKİŞ, RECEP; Yilmaz, U.

Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor

Atıf İçin Kopyala

ÜNEK İ. T., ÇELTİK A., Yener S., YAVUZŞEN T., Alacacioglu A., Cokmert S., ...Daha Fazla

JOURNAL OF BUON, cilt.14, sa.1, ss.135-138, 2009 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 1
Basım Tarihi: 2009
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.135-138
Anahtar Kelimeler: hypoglycemia, neuroendocrine tumor, somatostatin analogues, OCTREOTIDE, DIAGNOSIS
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Somatostatin and its long-acting analogues are effective in symptom control in patients with functional neuroendocrine tumors; they are also able to control tumor growth. Somatostatin analogues are safe and generally well tolerated. In some cases they may cause serious complications.